000294558 001__ 294558
000294558 005__ 20250311091351.0
000294558 0247_ $$2doi$$a10.1093/neuonc/noae238
000294558 0247_ $$2pmid$$apmid:39530475
000294558 0247_ $$2ISSN$$a1522-8517
000294558 0247_ $$2ISSN$$a1523-5866
000294558 0247_ $$2altmetric$$aaltmetric:170326287
000294558 037__ $$aDKFZ-2024-02333
000294558 041__ $$aEnglish
000294558 082__ $$a610
000294558 1001_ $$0P:(DE-He78)b769be55bb53da2335ffbfdab5ddb1b6$$aIppen, Franziska$$b0$$eFirst author
000294558 245__ $$aThe prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma.
000294558 260__ $$aOxford$$bOxford Univ. Press$$c2025
000294558 3367_ $$2DRIVER$$aarticle
000294558 3367_ $$2DataCite$$aOutput Types/Journal article
000294558 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1741680756_12600
000294558 3367_ $$2BibTeX$$aARTICLE
000294558 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294558 3367_ $$00$$2EndNote$$aJournal Article
000294558 500__ $$a#EA:B300#LA:B300# / 2025 Mar 7;27(3):743-754
000294558 520__ $$aHomozygous deletions of CDKN2A/B are known to predict poor prognosis in gliomas, but the impact of hemizygous deletions is less clear. This study aimed to evaluate the prognostic significance of hemizygous CDKN2A/B deletions in IDH-mutant low-grade astrocytomas and oligodendrogliomas.Tissue samples diagnosed as astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant, 1p/19q co-deleted CNS WHO grade 2 and 3 were collected from the archives of the Institute of Neuropathology in Heidelberg. DNA methylation analysis was performed on formalin-fixed paraffin-embedded (FFPE) samples. Evaluation of the CDKN2A/B locus was performed by visual inspection of copy-number plots derived from methylation-array data for each case. Hemizygous and homozygous losses were assessed in relation to whole chromosomal or larger segmental losses and gains in the chromosomal profile. Survival probabilities were assessed using the Kaplan-Meier method.A total of 334 low-grade glioma cases were identified, including 173 astrocytomas and 161 oligodendrogliomas. Hemizygous deletions in CDKN2A/B (37/173 in astrocytomas, 15/161 in oligodendrogliomas) did not confer significantly worse survival outcomes compared to CDKN2A/B wildtype cases in neither low grade astrocytoma (log-rank p= 0.2556; HR 2.29, 95% CI [0.76; 6.40], p= 0.135) nor oligodendroglioma (log-rank p= 0.2760; HR 0.17; 95% CI [0.01; 5.05]; p= 0.305), regardless of CNS WHO grade, which was further demonstrated on a subgroup of astrocytoma, IDH mutant CNS WHO 4 cases (log-rank p= 0.1680; HR 4.55, 95% CI [0.88; 24.51], p= 0.0689).Hemizygous CDKN2A/B deletions do not significantly worsen OS or PFS in IDH-mutant astrocytomas and oligodendrogliomas, CNS WHO grade 2 and 3.
000294558 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000294558 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294558 650_7 $$2Other$$aCDKN2A/B
000294558 650_7 $$2Other$$aIDH-mutant glioma
000294558 650_7 $$2Other$$ahemizygous deletion
000294558 650_7 $$2Other$$asurvival
000294558 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000294558 7001_ $$0P:(DE-He78)263d95a5b6ba4abce7abee7185b9630e$$aFriedel, Dennis$$b2$$udkfz
000294558 7001_ $$0P:(DE-He78)91f2043e3a8b3c5d31ec010fc634b118$$aGöbel, Kirsten$$b3$$udkfz
000294558 7001_ $$00000-0003-2269-5192$$aReuss, David$$b4
000294558 7001_ $$aHerold-Mende, Christel$$b5
000294558 7001_ $$aKrieg, Sandro$$b6
000294558 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b7$$udkfz
000294558 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b8$$udkfz
000294558 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b9$$udkfz
000294558 7001_ $$0P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aSuwala, Abigail Kora$$b10$$eLast author$$udkfz
000294558 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae238$$gp. noae238$$n3$$p743-754$$tNeuro-Oncology$$v27$$x1522-8517$$y2025
000294558 909CO $$ooai:inrepo02.dkfz.de:294558$$pVDB
000294558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b769be55bb53da2335ffbfdab5ddb1b6$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000294558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000294558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)263d95a5b6ba4abce7abee7185b9630e$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000294558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91f2043e3a8b3c5d31ec010fc634b118$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000294558 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-2269-5192$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000294558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000294558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000294558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000294558 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000294558 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000294558 9141_ $$y2024
000294558 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000294558 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000294558 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000294558 9202_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000294558 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000294558 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000294558 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x2
000294558 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000294558 9200_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000294558 980__ $$ajournal
000294558 980__ $$aVDB
000294558 980__ $$aI:(DE-He78)B300-20160331
000294558 980__ $$aI:(DE-He78)C060-20160331
000294558 980__ $$aI:(DE-He78)B320-20160331
000294558 980__ $$aI:(DE-He78)HD01-20160331
000294558 980__ $$aUNRESTRICTED